| Product NDC: | 13537-339 |
| Proprietary Name: | ESIKA |
| Non Proprietary Name: | Octinoxate, Oxybenzone, and Titanium Dioxide |
| Active Ingredient(s): | .07; .02; .02 g/g; g/g; g/g & nbsp; Octinoxate, Oxybenzone, and Titanium Dioxide |
| Administration Route(s): | TOPICAL |
| Dosage Form(s): | POWDER |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 13537-339 |
| Labeler Name: | Ventura Corporation (San Juan, P.R) |
| Product Type: | HUMAN OTC DRUG |
| FDA Application Number: | part352 |
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Start Marketing Date: | 20110517 |
| Package NDC: | 13537-339-02 |
| Package Description: | 1 CASE in 1 BOX (13537-339-02) > 6 g in 1 CASE (13537-339-01) |
| NDC Code | 13537-339-02 |
| Proprietary Name | ESIKA |
| Package Description | 1 CASE in 1 BOX (13537-339-02) > 6 g in 1 CASE (13537-339-01) |
| Product NDC | 13537-339 |
| Product Type Name | HUMAN OTC DRUG |
| Non Proprietary Name | Octinoxate, Oxybenzone, and Titanium Dioxide |
| Dosage Form Name | POWDER |
| Route Name | TOPICAL |
| Start Marketing Date | 20110517 |
| Marketing Category Name | OTC MONOGRAPH NOT FINAL |
| Labeler Name | Ventura Corporation (San Juan, P.R) |
| Substance Name | OCTINOXATE; OXYBENZONE; TITANIUM DIOXIDE |
| Strength Number | .07; .02; .02 |
| Strength Unit | g/g; g/g; g/g |
| Pharmaceutical Classes |